MeiraGTx Holdings plc
MeiraGTx is a clinical-stage genetic medicines company developing gene therapies for inherited and more common conditions. Its pipeline includes programs for radiation-induced xerostomia, Parkinson’s disease and inherited retinal diseases, as well as research in metabolic disorders, cancer, autoimmune diseases and long-term intractable pain. Its products use targeted local delivery of genetic medicines. MeiraGTx also develops a riboswitch platform that uses oral small molecules to control gene expression, and acquired assets and operations related to Smart Immune’s ProTcell cell therapy platform. The company operates genetic medicine manufacturing facilities in London, United Kingdom, and Shannon, Ireland, producing viral vectors, plasmid DNA and quality-control testing services for its programs and third parties. It makes money through collaboration and licensing agreements, including upfront and milestone payments and royalties, and through manufacturing and supply agreements. MeiraGTx is headquartered in New York, NY.
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Third Quarter 2026 Financial and Operational Results ● Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $9.95 ($0.56M total) on 2026-10-20 under a Rule 10b5-1 trading plan.
Goldman Sachs initiated coverage on MeiraGTx (MGTX) with a Neutral rating and $16.00 price target, up from $11.75. The company focuses on gene therapies for retinal diseases, xerostomia, and Parkinson’s. Analysts expect profitability this year. MeiraGTx secured a $400M investment deal with Oberland Capital, including capped royalties and equity. Other analysts maintain Buy ratings with higher price targets.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning MGTX (MeiraGTx Holdings plc). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MGTX coverage spans corporate actions, insider activity and earnings.
In the last 30 days, MGTX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($557K). The most active reporter was Giroux Richard, CFO & COO, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
New regulatory filing timeline and trial milestones could drive share volatility.
The insider sale may signal reduced confidence from a top executive, potentially pressuring the stock.
Analyst coverage and a sizable non‑dilutive capital raise could lift sentiment and support near‑term price appreciation.
Board appointment adds experienced biotech investor to governance, modest positive sentiment.
The filing discloses an insider sale by the CEO, which can modestly affect near-term sentiment but does not change fundamentals by itself.
AlphAI scores every news story that mentions MGTX with an AI model for sentiment and relevance, and aggregates insider trades from MeiraGTx Holdings plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Third Quarter 2026 Financial and Operational Results ● Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $9.95 ($0.56M total) on 2026-10-20 under a Rule 10b5-1 trading plan.
Goldman Sachs initiated coverage on MeiraGTx (MGTX) with a Neutral rating and $16.00 price target, up from $11.75. The company focuses on gene therapies for retinal diseases, xerostomia, and Parkinson’s. Analysts expect profitability this year. MeiraGTx secured a $400M investment deal with Oberland Capital, including capped royalties and equity. Other analysts maintain Buy ratings with higher price targets.
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, tod
Forbes Alexandria (PRESIDENT & CEO) sold 62,000 shares of MeiraGTx Holdings plc (MGTX) at $13.86 ($0.86M total) on 2026-08-18 under a Rule 10b5-1 trading plan.
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MeiraGTx Reports Second Quarter 2026 Financial and Operational Results - Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe
Giroux Richard (CFO & COO) sold 56,000 shares of MeiraGTx Holdings plc (MGTX) at $12.51 ($0.70M total) on 2026-07-21 under a Rule 10b5-1 trading plan.
MeiraGTx said it will receive up to $375m in non-dilutive capital from Oberland Capital via capped royalties, plus up to $25m in equity. An initial $135m was funded, including $125m in low single-digit royalties and a $10m equity stake. Additional payments total $150m tied to Phase II completion and regulatory approvals for AAV2-hAQP1 and bota-vec.
MeiraGTx Holdings (Nasdaq: MGTX) said it agreed with Oberland Capital for up to $400m to fund development/commercialization of AAV2-hAQP1 (RIX), bota-vec (XLRP) and AAV-AIPL1. Oberland will provide up to $375m in non-dilutive capped royalty funding and up to $25m equity, with additional tranches tied to 2027–2028 data/approvals.
MeiraGTx Holdings plc (MGTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 mgtx-20260630xex10d1.htm EX-10.1 Exhibit 10.1 Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Execution Version ROYALTY NOTE PUR
